References

A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups

10.1097/00005792-199111000-00002 · 1991 · External reference

Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes

10.1093/qjmed/77.1.1019 · 1990 · External reference

A review of antisynthetase syndrome-associated interstitial lung disease

10.3390/ijms25084453 · 2024 · External reference

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups

10.1136/annrheumdis-2017-211468 · 2017 · External reference

Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity

10.1016/j.autrev.2012.06.006 · 2012 · External reference

Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome

10.1371/journal.pone.0060442 · 2013 · External reference

Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review

10.1016/j.rmed.2020.105920 · 2020 · External reference

Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies

10.1080/08916930600622884 · 2006 · External reference

Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study

10.1007/s10067-017-3854-8 · 2018 · External reference

Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies

10.2169/internalmedicine.49.2889 · 2010 · External reference

Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy

10.1186/s12890-016-0325-y · 2016 · External reference

Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis

10.3899/jrheum.180778 · 2019 · External reference

Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease

10.1016/j.resinv.2019.10.004 · 2020 · External reference

Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease

2013 · External reference

Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease

10.1056/nejmc1900045 · 2019 · External reference

Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review

10.1016/j.semarthrit.2022.151959 · 2022 · External reference

Tofacitinib treatment for active dermatomyositis and anti-synthetase syndrome: a prospective cohort pilot study

10.1093/rheumatology/keaf046 · 2025 · External reference

Myositis-related interstitial lung disease and antisynthetase syndrome

10.1590/s1806-37132011000100015 · 2011 · External reference

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001

10.1164/ajrccm.165.2.ats01 · 2002 · External reference

Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: a retrospective cohort study

10.1016/j.semarthrit.2024.152474 · 2024 · External reference

Clinical features and risk factors of flare in anti-synthetase syndrome

10.1007/s10067-025-07398-9 · 2025 · External reference

Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life

10.1378/chest.06-1401 · 2007 · External reference

Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients

10.1136/annrheumdis-2012-201800 · 2014 · External reference

Pulmonary involvement in antisynthetase syndrome

10.1097/bor.0000000000000663 · 2019 · External reference

Clinical manifestations and treatment of antisynthetase syndrome

10.1016/j.berh.2020.101503 · 2020 · External reference

Remission and low disease activity definitions in adult idiopathic inflammatory myopathies: a narrative review by myositis clinical trials consortium (MCTC)

10.1016/j.autrev.2025.103879 · 2025 · External reference

Prednisolone and TAC versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: a randomized, open-label trial

10.1111/resp.13978 · 2021 · External reference

Synthesis and clinical application of small-molecule inhibitors of Janus kinase

10.1016/j.ejmech.2023.115848 · 2023 · External reference

Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review

10.55563/clinexprheumatol/hxin6o · 2023 · External reference

Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study

10.1183/13993003.01488-2024 · 2025 · External reference

Janus kinase inhibitors therapy in idiopathi inflammatory myopathies: a case series

10.55563/clinexprheumatol/0yu9gm · 2026 · External reference

Description and analysis of a novel subtype of the anti-synthetase syndrome characterized by frequent attacks of fever and systemic inflammation in a single-center cohort study

10.3389/fimmu.2021.729602 · 2021 · External reference

The safety of JAK-1 inhibitors

10.1093/rheumatology/keaa895 · 2021 · External reference